This work was supported by an NHLBI grant to K.M. and I.R.L. (1RO1HL119404). Carlos-Filipe Pereira was the recipient of a Revson Senior Biomedical Fellowship. We gratefully acknowledge the Mount Sinai hESC/iPSC Shared Resource Facility and S. D'Souza for assistance with materials and protocols. We also thank the Mount Sinai Flow Cytometry, Genomics, and Mouse facilities.

伦理学声明:小鼠细胞系衍生下列医学学院伊坎在西奈山的动物护理指导原则，并应遵守任何主办机构来完成。 C57BL / 6小鼠1.鼠标胚胎成纤维细胞（MEF）隔离<ol><li>设置定时交配13。一旦阴道塞的可视化，可以考虑0.5本节。 </li><li>分离插头上的日期插入女性和检查他们在10-11天，以确认妊娠。 </li><li>在13.5-14.5日通过CO安乐死怀孕的雌性小鼠吸入2颈椎脱位。 </li><li>浸泡怀孕雌性腹部用70％乙醇，解剖用无菌剪刀和镊子向下中线腹腔，并手术移除含有胚胎14子宫角。轻轻取出胚胎的同时切断剩余的腹部组织。 注:每边约恢复8胚胎4。 </li><li>放置子宫^ h含在10cm皿用5-10毫升无菌冷冻磷酸盐缓冲盐水（PBS）的胚胎orns。 </li><li>用无菌剪刀和镊子，使沿子宫角切口携带的胚胎囊隔离。转移囊到一个新的10cm皿5-10毫升无菌冷冻PBS并放置冰上。 </li><li>将几个囊到一个新的10cm皿5-10毫升无菌冷冻的PBS。用无菌剪刀和镊子轻轻划开囊（无切削太深），以免刺入胚胎。 </li><li>通过切割脐带分离从胎盘的胚胎。 </li><li>胚胎转移到含有5-10毫升冷冻PBS的新10cm皿和冰离开，而完成剩余解剖。 </li><li>斩首使用无菌镊子胚胎。小心砍掉胚胎用无菌剪刀和镊子，从断头地区开始开拓腹部正中线。钳位置下方ŧ他内脏器官（包括心脏，肝脏和肺）和刮出来15。 </li><li>切割用剪刀和镊子，并转移到含有10ml胰蛋白酶的50ml锥形管中剩余的组织切成小块。 </li><li>吸管上下10ml的移液管20-30次混合和分离组织。 </li><li>孵育在37℃的水浴的组织和胰蛋白酶混合物45分钟，偶尔漩。 </li><li>吸取上下10ml的移液管约5分钟以混合的内容。 </li><li>添加胰蛋白酶的细胞至3x标准的Dulbecco改良的Eagle培养基（DMEM）和10％胎牛血清（FBS），体积10微克/毫升青霉素/链霉素（P / S）和1mM L-谷氨酰胺（L-GLUT）中10厘米菜（〜10毫升）中，并在37℃下培养直至汇合（约2-4天）。文化约每10 cm培养皿1-2胚胎。 注:冻结的细胞，一旦板块都汇合。冷冻细胞可解冻并传代2次以上。细胞可以或者是解冻后冷冻前分裂2次，然后一次。 </li></ol> 2.病毒生产<ol><li>扩大293T细胞中，用10ml含10％FBS，1％P / S，和1％L- GLUT用于转染10的9cm培养皿中。 <ol><li> Trypsinize 293T细胞用2ml胰蛋白酶，孵育在37℃下5分钟，收集细胞到15ml试管，旋在300 XG和板适当（10毫升，每10cm皿）。 </li></ol></li><li> 24小时在转染前，分割293T细胞1的汇合10cm平板:6和种子于10cm明胶包衣（在PBS中的0.1％明胶）板。 注:每个病毒4板是必需的。 <ol><li>在明胶涂层板，至少添加将2ml 0.1％明胶溶液涂覆10厘米板的底部。孵育在37℃下至少20分钟。吸掉明胶之前，加入细胞板。 </li></ol></li><li>在15ml管中，加入84微克质粒（例如GATA2，Gfi1b，cFos的，或ETV6（子克隆到pFUW-TETO VECT或16）或FUW-M2rtTA 17），84微克psPAX2和42微克pMD2.G.加水（H 2 O），以弥补容积〜2毫升。准备一个管各因素（ 如 GATA2，Gfi1b，首席财务官，ETV6和FUW-M2rtTA）。 </li><li>加入250微升2M氯化钙2到包含所选基因的84微克组成2 mL萃取混合物中各管（GATA2，Gfi1b，首席财务官，ETV6或FUW-M2rtTA）+ 84微克psPAX2 + 42微克pMD2.G + H 2 O 。 </li><li>使用插入吸管援助巴斯德吸管，释放气泡进入2.25毫升DNA + H 2 O + 2M的氯化钙2混合。由于正在产生的气泡，将贴在玻璃吸管P1000的的前端，慢慢地喷射2毫升100毫N，N-双（2-羟乙基）-2-氨基乙烷磺酸（BES）盐水走在巴斯德吸管1毫升一次。 </li><li>孵育在培养罩所有管在室温下至少15分钟。 注:4.25毫升混合物（现在DNA + H 2 O + 2M 氯化钙 </子&gt; + BES生理盐水）将看上去有点浑浊。 </li><li>作为混合物孵化，吸媒体关闭293T板和加入10 mL的DMEM + 10％FBS + 1 2mM L-谷氨酰胺+ 25nM的氯喹。 注:该介质不包含P / S。 </li><li>温育至少15分钟后（或直到上293T细胞变化的媒体），添加4.25毫升DNA + H 2 O +的2M氯化钙2 + BES盐水混合物逐滴至293T细胞，跨越每个管4细胞板均匀分布（即略超过1毫升，每板中的混合物的）。 </li><li>在37℃的板过夜（O / N）。 </li><li>后24小时孵化，用4ml DMEM标准（见步骤1.15）替换所有板块的媒体。 </li><li>保存在32℃培养箱细胞从现在开始。 </li><li> 24小时步后2.10，媒体收集到单独的50ml试管。用4ml标准的DMEM替换从每块板收集的媒体。 注:每个初始管混合物，结果4板在16毫升收集媒体。 <ol><li>一个压脚提升培养12小时，重新收集媒体到同一个50ml试管和另外4 mL标准的DMEM取代。 </li><li>培养12小时后，收集媒体和添加到相同50ml试管。 注:各管应包含约48毫升含有病毒的媒介。 </li></ol></li><li>要通过0.45微米的低蛋白结合过滤器集中收集病毒，第一个过滤器收集到的介质。 </li><li>倾含病毒进入的病毒浓度离心管（约16毫升一时间）过滤介质。 </li><li>旋在4000 XG在4℃下25分钟，取出流通。 注意:浓缩介质和病毒的一种小体积将在过滤器是可见的。 </li><li>另外16毫升的过滤含病毒介质的添加到残留在过滤器中的浓缩培养基+病毒量和通过反转所述管混合。 </li><li>旋转管再次在4℃下4000×g离心25分钟，并丢弃流过。 </li><li>添加过滤剩余收集浓缩的培养基+病毒量留在过滤器中并通过反相管混匀。 </li><li>在4℃下10-20分钟旋转一次在4000 xg离心（取决于在过滤器的卷上），并确保浓缩培养基+病毒残留在过滤器的剩余体积为约1ml。如果大于1毫升浓培养基+病毒的保留在过滤器，以4,000 xg离心再次旋转1分钟，并重复直到1毫升在过滤器中留下。 </li><li>等份加入200μl浓缩病毒的进入1.5毫升管，并在-80℃冷冻或立即使用。 </li></ol> 3. MEF重编程<ol><li>预涂层6孔板用0.5ml 0.1％明胶的PBS中，每孔，确保明胶覆盖的阱的整个区域。在37℃培养箱放置并孵育至少20分钟。孵化后，取出板和吸出明胶。 </li><li>与以每孔25,000个细胞的密度标准DMEM板的MEF（150,000个细胞每6孔板）上从步骤3.1凝胶化6孔板（多个），并允许沉降O / N在37℃培养箱。 </li><li>通过混合50微升M2rtTA其余50微升GATA2，Gfi1b，cFos的，和ETV6的混合（每12.5微升）制备100μl的病毒鸡尾酒。 </li><li>由MEF吸媒体和加入2毫升的标准DMEM 8微克/毫升聚凝胺。 </li><li>转导的MEF平板的每个孔以15微升病毒鸡尾酒的，并在37°C孵育O / N。 注意:这是重编程过程的第0天。 </li><li>在第1天，在培养16-20小时后，用补充有1μg/ ml的阿霉素每阱2毫升的新鲜标准的DMEM替换培养基。 </li><li>制备添加有氢化可的松（10 -6 M），100ng / ml的干细胞因子（SCF），100纳克/毫升FMS相关酪氨酸激酶3配体（FLT3L），20纳克/毫升白细胞介素-3（IL-造血培养基3），20纳克/毫升白细胞介素-6（IL-6），和1μg/ ml的阿霉素。 </li><li>第4天aspiratE从每个孔中的介质和洗涤细胞用每孔1ml的PBS。 </li><li>抽吸PBS中，离解，用1毫升，每孔0.05％胰蛋白酶的细胞，并收集细胞。 </li><li>计数细胞用血细胞计数器，旋在300×g离心5分钟，重新悬浮于12ml在步骤3.7中所述的造血介质和板每6孔板60,000个细胞上0.1％明胶包被的平板（2毫升，每孔10,000细胞，每孔）。 </li><li>用新鲜的造血补充的文化传媒，每6天为文化的持续时间（35〜36天）更换介质。 </li><li>分析或者中间细胞或新出现的造血细胞样细胞通过免疫染色12，FACS分析8,12，定量RT-PCR检测12，和mRNA测序12确认采集hemogenic内皮或HSC状的标记和基因表达。 </li></ol> 4.胎盘聚集和菌落形成单位（CFU）的甲基纤维素测定<ol><li>从怀孕的C5解剖胎盘7BL / 6小鼠如先前所述18在E12.5和保持组织在冰上。 </li><li>启动胎盘解离19，洗净胎盘组织在2-5毫升0.2％I型胶原酶的PBS，用20％FBS和与由通过针头传代胎盘和PBS装入5ml的注射器的18G针机械解离至少3次。 </li><li>机械解离后，保持在2-5毫升胶原酶溶液的胎盘细胞在37℃下1.5小时。 </li><li>传代细胞通过20-25g的针头装配到5毫升注射器数次以进一步机械解离的胎盘细胞。 </li><li>通过70微米的细胞过滤器过滤单细胞悬液。 </li><li>计数与血球细胞中并在2000 cGy的照射有丝分裂失活20。 </li><li> 10毫升补充有100纳克/毫升的SCF，100纳克/毫升FLT3L，20纳克/ ml的IL-3，20纳克/ ml的IL-6和10ng / ml的血小板生成素（TPO）造血培养基添加到10cm的碟。 注:DOX未在该阶段需要。 </li><li>直接放置一个0.65微米的过滤器对造血培养基在盘中，允许其浮动以创建一个液 - 气界面，并设置菜一边。 </li><li>离解在步骤3.8-3.10描述每日25转导的MEF（来自步骤3.11衍生），并与来自步骤4.6胎盘集合体167,000细胞混合转导的MEFs 33000（1:6比）。 </li><li>要生成汇总18,21，先降速的MEF和胎盘细胞混合物从步骤4.9在300×克5分钟。吸媒体，并使用P200吸管悬浮沉淀的细胞在30-50微升标准的DMEM，绘制单细胞悬液到200微升nonbevelled的枪头。 </li><li>闭塞用石蜡膜枪头。放置阻塞尖入15ml离心管，并在尖端的覆盖端降速5分钟，在300 xg离心所以粒料形式。 </li><li>精心的15ml试管和地点卸下吸头尖端到P200移液管的端部。丢弃石蜡膜，然后从步骤4.8挤出细胞沉淀到浮置滤波器。 注:每板式过滤器最多3聚集。 </li><li>培养在浮动0.65微米的过滤器为4-5天的聚集体在37℃，5％的CO 2。 </li><li>收集用细胞刮刀的聚集物（至多3％滤波器），将它们结合起来，并用0.2％胶原酶消化，以下作为与整个胎盘做以解离细胞的相同的协议（步骤4.2-4.5）。 </li><li>解离后，洗聚集体与2-5毫升的PBS补充有5％FBS和300 XG降速细胞5分钟。 </li><li>悬浮于500μl的DMEM的聚集体无FBS，P / S，或L-GLUT。借此将500μl再悬浮，并将其添加到补充有10ng / ml的TPO，精心避免气泡的形成3毫升1％甲基纤维素的介质。在3 35×10mm的非处理培养皿该混合物的板等体积CFU测定12。 </li><li>作为对照，将培养照射胎盘聚集体没有如在步骤4.7-4.16如上所述重新编程的MEF 4-5天，并装在CFU实验中混合。 注:这些聚集本身并不能形成菌落。 </li><li>算手动后培养10-14天的显微镜，在37℃，5％CO 2条件下的造血集落。 </li><li>细胞离心涂片22拾取菌落来显示单个细胞的形态表型。 </li></ol>

<ol>
	<li>Zovein, A. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fate+tracing+reveals+the+endothelial+origin+of+hematopoietic+stem+cells.">Fate tracing reveals the endothelial origin of hematopoietic stem cells.</a> Cell Stem Cell. 3 (6), 625-636 (2008).</li><li>Bertrand, J. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Haematopoietic+stem+cells+derive+directly+from+aortic+endothelium+during+development.">Haematopoietic stem cells derive directly from aortic endothelium during development.</a> Nature. 464 (7285), 108-111 (2010).</li><li>Papapetrou, E. P., Sadelain, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reconstructing+blood+from+induced+pluripotent+stem+cells.">Reconstructing blood from induced pluripotent stem cells.</a> F1000 Med Rep. 2, (2010).</li><li>Szabo, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Direct+conversion+of+human+fibroblasts+to+multilineage+blood+progenitors.">Direct conversion of human fibroblasts to multilineage blood progenitors.</a> Nature. 468 (7323), 521-526 (2010).</li><li>Mitchell, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+evidence+for+OCT4-induced+plasticity+in+adult+human+fibroblasts+required+for+direct+cell+fate+conversion+to+lineage+specific+progenitors.">Molecular evidence for OCT4-induced plasticity in adult human fibroblasts required for direct cell fate conversion to lineage specific progenitors.</a> Stem Cells. 32 (8), 2178-2187 (2014).</li><li>Takahashi, K., Yamanaka, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+pluripotent+stem+cells+from+mouse+embryonic+and+adult+fibroblast+cultures+by+defined+factors.">Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</a> Cell. 126 (4), 663-676 (2006).</li><li>Takahashi, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+pluripotent+stem+cells+from+adult+human+fibroblasts+by+defined+factors.">Induction of pluripotent stem cells from adult human fibroblasts by defined factors.</a> Cell. 131 (5), 861-872 (2007).</li><li>Qiu, J., Papatsenko, D., Niu, X., Schaniel, C., Moore, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Divisional+history+and+hematopoietic+stem+cell+function+during+homeostasis.">Divisional history and hematopoietic stem cell function during homeostasis.</a> Stem Cell Reports. 2 (4), 473-490 (2014).</li><li>Riddell, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reprogramming+committed+murine+blood+cells+to+induced+hematopoietic+stem+cells+with+defined+factors.">Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors.</a> Cell. 157 (3), 549-564 (2014).</li><li>Sandler, V. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reprogramming+human+endothelial+cells+to+haematopoietic+cells+requires+vascular+induction.">Reprogramming human endothelial cells to haematopoietic cells requires vascular induction.</a> Nature. 511 (7509), 312-318 (2014).</li><li>Daniel, M. G., Pereira, C. F., Lemischka, I. R., Moore, K. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Making+a+Hematopoietic+Stem+Cell.">Making a Hematopoietic Stem Cell.</a> Trends Cell Biol. , (2015).</li><li>Pereira, C. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+a+hemogenic+program+in+mouse+fibroblasts.">Induction of a hemogenic program in mouse fibroblasts.</a> Cell Stem Cell. 13 (2), 205-218 (2013).</li><li>Mader, S. L., Libal, N. L., Pritchett-Corning, K., Yang, R., Murphy, S. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Refining+timed+pregnancies+in+two+strains+of+genetically+engineered+mice.">Refining timed pregnancies in two strains of genetically engineered mice.</a> Lab Anim (NY. 38 (9), 305-310 (2009).</li><li>Jain, K., Verma, P. J., Liu, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Isolation+and+handling+of+mouse+embryonic+fibroblasts).">Isolation and handling of mouse embryonic fibroblasts).</a> Methods Mol Biol. 1194, 247-252 (2014).</li><li>Bryja, V., Bonilla, S., Arenas, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Derivation+of+mouse+embryonic+stem+cells.">Derivation of mouse embryonic stem cells.</a> Nat Protoc. 1 (4), 2082-2087 (2006).</li><li>Carey, B. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reprogramming+of+murine+and+human+somatic+cells+using+a+single+polycistronic+vector.">Reprogramming of murine and human somatic cells using a single polycistronic vector.</a> Proc Natl Acad Sci U S A. 106 (1), 157-162 (2009).</li><li>Hockemeyer, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+drug-inducible+system+for+direct+reprogramming+of+human+somatic+cells+to+pluripotency.">A drug-inducible system for direct reprogramming of human somatic cells to pluripotency.</a> Cell Stem Cell. 3 (3), 346-353 (2008).</li><li>Taoudi, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Extensive+hematopoietic+stem+cell+generation+in+the+AGM+region+via+maturation+of+VE-cadherin+CD45++pre-definitive+HSCs.">Extensive hematopoietic stem cell generation in the AGM region via maturation of VE-cadherin+CD45+ pre-definitive HSCs.</a> Cell Stem Cell. 3 (1), 99-108 (2008).</li><li>Gekas, C., K, E. R., H, K. A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Isolation+and+analysis+of+hematopoietic+stem+cells+from+the+placenta.">Isolation and analysis of hematopoietic stem cells from the placenta.</a> J Vis Exp. (16), (2008).</li><li>Lewis, I. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Umbilical+cord+blood+cells+capable+of+engrafting+in+primary,+secondary,+and+tertiary+xenogeneic+hosts+are+preserved+after+ex+vivo+culture+in+a+noncontact+system.">Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system.</a> Blood. 97 (11), 3441-3449 (2001).</li><li>Sheridan, J. M., Taoudi, S., Medvinsky, A., Blackburn, C. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel+method+for+the+generation+of+reaggregated+organotypic+cultures+that+permits+juxtaposition+of+defined+cell+populations.">A novel method for the generation of reaggregated organotypic cultures that permits juxtaposition of defined cell populations.</a> Genesis. 47 (5), 346-351 (2009).</li><li>Koh, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Preparation+of+cells+for+microscopy+using+cytospin.">Preparation of cells for microscopy using cytospin.</a> Methods Enzymol. 533, 235-240 (2013).</li><li>Orkin, S. H., Zon, L. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Hematopoiesis:+an+evolving+paradigm+for+stem+cell+biology.">Hematopoiesis: an evolving paradigm for stem cell biology.</a> Cell. 132 (4), 631-644 (2008).</li><li>Martinez-Agosto, J. A., Mikkola, H. K., Hartenstein, V., Banerjee, U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+hematopoietic+stem+cell+and+its+niche:+a+comparative+view.">The hematopoietic stem cell and its niche: a comparative view.</a> Genes Dev. 21 (23), 3044-3060 (2007).</li><li>Butler, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+a+vascular+niche+platform+for+expansion+of+repopulating+human+cord+blood+stem+and+progenitor+cells.">Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells.</a> Blood. 120 (6), 1344-1347 (2012).</li><li>Gori, J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Vascular+niche+promotes+hematopoietic+multipotent+progenitor+formation+from+pluripotent+stem+cells.">Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells.</a> J Clin Invest. 125 (3), 1243-1254 (2015).</li><li>Bar-Nur, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lineage+conversion+induced+by+pluripotency+factors+involves+transient+passage+through+an+iPSC+stage.">Lineage conversion induced by pluripotency factors involves transient passage through an iPSC stage.</a> Nat Biotechnol. 33 (7), 761-768 (2015).</li><li>Maza, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Transient+acquisition+of+pluripotency+during+somatic+cell+transdifferentiation+with+iPSC+reprogramming+factors.">Transient acquisition of pluripotency during somatic cell transdifferentiation with iPSC reprogramming factors.</a> Nat Biotechnol. 33 (7), 769-774 (2015).</li><li>Kim, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Epigenetic+memory+in+induced+pluripotent+stem+cells.">Epigenetic memory in induced pluripotent stem cells.</a> Nature. 467 (7313), 285-290 (2010).</li><li>Vaskova, E. A., Stekleneva, A. E., Medvedev, S. P., Zakian, S. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term="Epigenetic+memory:+phenomenon+in+induced+pluripotent+stem+cells.">"Epigenetic memory: phenomenon in induced pluripotent stem cells.</a> Acta Naturae. 5 (4), 15-21 (2013).</li><li>Elcheva, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Direct+induction+of+haematoendothelial+programs+in+human+pluripotent+stem+cells+by+transcriptional+regulators.">Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators.</a> Nat Commun. 5, 4372 (2014).</li><li>Vereide, D. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+expandable,+inducible+hemangioblast+state+regulated+by+fibroblast+growth+factor.">An expandable, inducible hemangioblast state regulated by fibroblast growth factor.</a> Stem Cell Reports. 3 (6), 1043-1057 (2014).</li><li>Batta, K., Florkowska, M., Kouskoff, V., Lacaud, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Direct+reprogramming+of+murine+fibroblasts+to+hematopoietic+progenitor+cells.">Direct reprogramming of murine fibroblasts to hematopoietic progenitor cells.</a> Cell Rep. 9 (5), 1871-1884 (2014).</li></ol>

The authors have no conflict of interest to disclose.

从容易实现的体细胞产生骨髓干细胞从头提供了一个独特的方法来研究体外造血，并有机会可能这个技术应用到人的制度。这个翻译将产生一个新的工具来研究人类血液病在培养皿中，以及提供药物测试平台和基因定位机会以治疗与新疗法或HSC移植众多障碍。在该领域，最近的研究上的能力扩展到产生骨髓干细胞从头 ，展示的重编程过程的几个特征的重要性。这些措施包括起...

造血是一个复杂的发育过程，其中的造血干细胞（HSCs）出芽存在于各种胚胎造血网站，如主动脉-性腺-中肾和胎盘1,2 hemogenic内皮。无法培养造血干细胞在体外阻止此过程的深入分析，以及这些研究的临床应用。规避此限制，先前的研究试图获得造血干细胞从头或者通过使用重新编程媒体4,5-多能干细胞（的PSCs）3，或在体细胞诱导的可塑性和定向分化的分化。这些研究，但是，不产生临床安全engraftable细胞或允许最终造血发育研究"的菜。" 从体细胞的成纤维细胞p由山及其同事建立的新颖工作以产生诱导性多能干细胞（iPS细胞）rovides转录因子（TF）在重编程的细胞命运6,7-基于过表达策略的框架。这项工作已经促使调查人员在若干领域通过容易获得体细胞重编程TF产生细胞类型的选择。这里所描述的重编程策略的目标是诱导从使用具有转换这些发现对人体系统重新编程特定病人的成纤维细胞，以研究人类造血体外的目标基于TF重新编程的方法和小鼠体细胞hemogenic过程生成患者特异性血制品用于疾病建模，药物检验，和干细胞移植。 第一步，以确保在该小鼠系统适当重新编程是开发担任的读出为CD34的表达，在内皮祖细胞和造血干细胞的已知标记的报道一致。要做到这一点，huCD34-和tTA的TETO-H2BGFP转基因小鼠系被用于与Generate双转基因小鼠胚胎成纤维细胞（MEF），现在表示34 / H2BGFP，发荧光绿于CD34启动子8的激活。这允许各种已知被要求在不同的点造血说明书和发育过程中的TF的筛选。在PMX retrovial载体18开始的TF（通过文献挖掘和GFP标签保留从之前造血干细胞的分析确定描述34 / H2BGFP只），34 / H2BGFP MEF中与AFT024 HSC-支持基质细胞的所有因素和培养转。检测34 / H2BGFP激活后，转录因子随后从重新编程的鸡尾酒删除，直到转录因子的活化记者一组最佳被确定。此初始屏幕之后，将因素转移到DOX诱导pFUW载体系统，以允许转录因子的控制的表达。由于这两个DOX可控系统是不兼容的（34 / H2BGFP细胞和pFUW诱导矢量），由MEF野生型C57BL / 6小鼠被要求。此外，还必须提供适当的微环境，使hemogenesis继续创造多向祖细胞克隆。 试图体细胞重编程到造血干细胞和祖细胞（骨髓干细胞）目前的研究已达到成功的9-11不同层次。迄今为止，小鼠和具有长期和自我更新的重新填充能力的人类移植骨髓干细胞的产生尚未使用同一组转录因子实现。在这个协议中，我们提供先前建立的策略的详细描述可重复地诱导hemogenesis在MEF中。我们证明，引进了全套转录因子（GATA2，Gfi1b，首席财务官和ETV6）的最小的能够煽动体外复杂的发展计划，规定了可发展的造血和造血重新编程的临床应用，可进一步研究12的平台。

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>DMEM</td>
			<td>Invitrogen</td>
			<td>11965-092</td>
			<td></td>
		</tr>
		<tr>
			<td>0.45uM filters</td>
			<td>Corning</td>
			<td>430625</td>
			<td></td>
		</tr>
		<tr>
			<td>Amicon Ultra centrifugal filters</td>
			<td>Millipore</td>
			<td>UFC900324</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin/Streptomycin</td>
			<td>Invitrogen</td>
			<td>15140-122</td>
			<td></td>
		</tr>
		<tr>
			<td>L-Glutamine</td>
			<td>Invitrogen</td>
			<td>25030-081</td>
			<td></td>
		</tr>
		<tr>
			<td>FBS</td>
			<td>Gemini&#39;s Benchmark</td>
			<td>100-106</td>
			<td></td>
		</tr>
		<tr>
			<td>PBS</td>
			<td>Life Technologies</td>
			<td>14190-144</td>
			<td></td>
		</tr>
		<tr>
			<td>18G needles</td>
			<td>BD</td>
			<td>305195</td>
			<td></td>
		</tr>
		<tr>
			<td>20G needles</td>
			<td>BD</td>
			<td>305175</td>
			<td></td>
		</tr>
		<tr>
			<td>25G needles</td>
			<td>BD</td>
			<td>305125</td>
			<td></td>
		</tr>
		<tr>
			<td>Collagenase Type I</td>
			<td>Sigma</td>
			<td>C0130-100MG</td>
			<td></td>
		</tr>
		<tr>
			<td>TrypLE Express</td>
			<td>Invitrogen</td>
			<td>12605-010</td>
			<td></td>
		</tr>
		<tr>
			<td>Myelocult media</td>
			<td>Stem Cell Technologies</td>
			<td>M5300</td>
			<td></td>
		</tr>
		<tr>
			<td>SCF</td>
			<td>R &#38; D Systems</td>
			<td>455-MC</td>
			<td></td>
		</tr>
		<tr>
			<td>Flt3L</td>
			<td>R &#38; D Systems</td>
			<td>427-FL</td>
			<td></td>
		</tr>
		<tr>
			<td>IL-3</td>
			<td>R &#38; D Systems</td>
			<td>403-ML</td>
			<td></td>
		</tr>
		<tr>
			<td>IL-6</td>
			<td>R &#38; D Systems</td>
			<td>406-ML</td>
			<td></td>
		</tr>
		<tr>
			<td>TPO</td>
			<td>R &#38; D Systems</td>
			<td>488-TO</td>
			<td></td>
		</tr>
		<tr>
			<td>Doxycycline</td>
			<td>Sigma</td>
			<td>D9891-1G</td>
			<td></td>
		</tr>
		<tr>
			<td>Polybrene (hexadimethrine bromide)</td>
			<td>Sigma</td>
			<td>AL-118</td>
			<td></td>
		</tr>
		<tr>
			<td>Durapore 0.65uM membrane filters</td>
			<td>Millipore</td>
			<td>DVPP14250</td>
			<td></td>
		</tr>
		<tr>
			<td>Methylcellulose media</td>
			<td>Stem Cell Technologies</td>
			<td>Methocult M3434</td>
			<td></td>
		</tr>
		<tr>
			<td>Hydrocortisone</td>
			<td>Stem Cell Technologies</td>
			<td>07904</td>
			<td></td>
		</tr>
		<tr>
			<td>C57BL/6 mice</td>
			<td>The Jackson Laboratory</td>
			<td>000664</td>
			<td></td>
		</tr>
		<tr>
			<td>Gelatin</td>
			<td>Sigma</td>
			<td>G-1890 100g</td>
			<td></td>
		</tr>
		<tr>
			<td>pFUW-tetO</td>
			<td>Addgene</td>
			<td>Plasmid #20321</td>
			<td></td>
		</tr>
		<tr>
			<td>Gata2</td>
			<td>Origene</td>
			<td>MR226728</td>
			<td></td>
		</tr>
		<tr>
			<td>Gfi1b</td>
			<td>Origene</td>
			<td>MR204861</td>
			<td></td>
		</tr>
		<tr>
			<td>cFos&#160;</td>
			<td>Addgene</td>
			<td>Plasmid #19259</td>
			<td></td>
		</tr>
		<tr>
			<td>Etv6</td>
			<td>Origene</td>
			<td>MR207053</td>
			<td></td>
		</tr>
		<tr>
			<td>psPAX2</td>
			<td>Addgene</td>
			<td>Plasmid #12260</td>
			<td></td>
		</tr>
		<tr>
			<td>pMD2.G</td>
			<td>Addgene</td>
			<td>Plasmid #12259</td>
			<td></td>
		</tr>
		<tr>
			<td>CaCl2</td>
			<td>Sigma</td>
			<td>C5670-100g</td>
			<td></td>
		</tr>
		<tr>
			<td>FUW-M2rtTA</td>
			<td>Addgene</td>
			<td>Plasmid #20342</td>
			<td></td>
		</tr>
		<tr>
			<td>35 x 10 mm culture dishes</td>
			<td>Thermo Scientific</td>
			<td>171099</td>
			<td></td>
		</tr>
	</tbody>
</table>

reprogramming mouse embryonic fibroblasts with transcription factors to induce a hemogenic program

This protocol details the induction of a hemogenic program in mouse embryonic fibroblasts (MEFs) via overexpression of transcription factors (TFs). We first designed a reporter screen using MEFs from human CD34-tTA/TetO-H2BGFP (34/H2BGFP) double transgenic mice. CD34+ cells from these mice label H2B histones with GFP, and cease labeling upon addition of doxycycline (DOX). MEFS were transduced with candidate TFs and then observed for the emergence of GFP+ cells that would indicate the acquisition of a hematopoietic or endothelial cell fate. Starting with 18 candidate TFs, and through a process of combinatorial elimination, we obtained a minimal set of factors that would induce the highest percentage of GFP+ cells. We found that Gata2, Gfi1b, and cFos were necessary and the addition of Etv6 provided the optimal induction. A series of gene expression analyses done at different time points during the reprogramming process revealed that these cells appeared to go through a precursor cell that underwent an endothelial to hematopoietic transition (EHT). As such, this reprogramming process mimics developmental hematopoiesis "in a dish," allowing study of hematopoiesis in vitro and a platform to identify the mechanisms that underlie this specification. This methodology also provides a framework for translation of this work to the human system in the hopes of generating an alternative source of patient-specific hematopoietic stem cells (HSCs) for a number of applications in the treatment and study of hematologic diseases.

造血是一个复杂的发展过程，在不同的胚胎网站开始。 Hemogenic内皮细胞存在于这些网站，并给通过手机初露头角的23引起造血干细胞。这个过程目前还无法通过将造血干细胞或造血前体文化，因此需要一种方法在体外以某种方式获得这些细胞进行复制，或者通过HSPC 体外扩增或产生从头 。该协议表明了我们试图通过获得TF表达，这些细胞在MEF中...

Watch this Scientific Journal Video about Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program at JoVE.com

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

The protocol described here details the induction of a hemogenic program in mouse embryonic fibroblasts via overexpression of a minimal set of transcription factors. This technology may be translated to the human system to provide platforms for future study of hematopoiesis, hematologic disease, and hematopoietic stem cell transplant.

重新编程的小鼠胚胎成纤维细胞转录因子诱导Hemogenic计划

This protocol details the induction of a hemogenic program in mouse embryonic fibroblasts (MEFs) via overexpression of transcription factors (TFs). We ...

reprogramming-mouse-embryonic-fibroblasts-with-transcription-factors

Research

JoVE Journal

Developmental Biology

7.1K 次观看.  Icahn School of Medicine at Mount Sinai. The protocol described here details the induction of a hemogenic program in mouse embryonic fibroblasts via overexpression of a minimal set of transcription factors. This technology may be translated to the human system to provide platforms for future study of hematopoiesis, hematologic disease, and hematopoietic stem cell transplant.

视频: Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Direct Induction of Hemogenic Endothelium and Blood by Overexpression of Transcription Factors in Human Pluripotent Stem Cells

During development, hematopoietic cells arise from a specialized subset of endothelial cells, hemogenic endothelium (HE). Modeling HE development in vitro is essential for mechanistic studies of the endothelial-hematopoietic transition and hematopoietic specification. Here, we describe a method for the efficient induction of HE from human pluripotent stem cells (hPSCs) by way of overexpression of different sets of transcription factors. The combination of ETV2 and GATA1 or GATA2 TFs is used to induce HE with pan-myeloid potential, while a combination of GATA2 and TAL1 transcription factors allows for the production of HE with erythroid and megakaryocytic potential. The addition of LMO2 to GATA2 and TAL1 combination substantially accelerates differentiation and increases erythroid and megakaryocytic cells production. This method provides an efficient and rapid means of HE induction from hPSCs and allows for the observation of the endothelial-hematopoietic transition in a culture dish. The protocol includes hPSCs transduction procedures and post-transduction analysis of HE and blood progenitors.

This protocol describes the efficient induction of hemogenic endothelium and multipotential hematopoietic progenitors from human pluripotent stem cells via the forced expression of transcription factors.

Hemogenic内皮细胞直接诱导和血液中转录因子在人多能干细胞表达

During development, hematopoietic cells arise from a specialized subset of endothelial cells, hemogenic endothelium (HE). Modeling HE development in vitro ...

科研

发育生物学

Generating CRISPR/Cas9 Mediated Monoallelic Deletions to Study Enhancer Function in Mouse Embryonic Stem Cells

Enhancers control cell identity by regulating tissue-specific gene expression in a position and orientation independent manner. These enhancers are often located distally from the regulated gene in intergenic regions or even within the body of another gene. The position independent nature of enhancer activity makes it difficult to match enhancers with the genes they regulate. Deletion of an enhancer region provides direct evidence for enhancer activity and is the gold standard to reveal an enhancer's role in endogenous gene transcription. Conventional homologous recombination based deletion methods have been surpassed by recent advances in genome editing technology which enable rapid and precisely located changes to the genomes of numerous model organisms. CRISPR/Cas9 mediated genome editing can be used to manipulate the genome in many cell types and organisms rapidly and cost effectively, due to the ease with which Cas9 can be targeted to the genome by a guide RNA from a bespoke expression plasmid. Homozygous deletion of essential gene regulatory elements might lead to lethality or alter cellular phenotype whereas monoallelic deletion of transcriptional enhancers allows for the study of cis-regulation of gene expression without this confounding issue. Presented here is a protocol for CRISPR/Cas9 mediated deletion in F1 mouse embryonic stem (ES) cells (Mus musculus129 x Mus castaneus). Monoallelic deletion, screening and expression analysis is facilitated by single nucleotide polymorphisms (SNP) between the two alleles which occur on average every 125 bp in these cells.

Experimental validation of enhancer activity is best approached by loss-of-function analysis. Presented here is an efficient protocol that uses CRISPR/Cas9 mediated deletion to study allele-specific regulation of gene transcription in F1 ES cells which contain a hybrid genome (Mus musculus129 x Mus castaneus).

生成CRISPR / Cas9介导的单等位基因缺失来研究小鼠胚胎干细胞功能增强

Enhancers control cell identity by regulating tissue-specific gene expression in a position and orientation independent manner. These enhancers are often ...

Isolation of Murine Embryonic Hemogenic Endothelial Cells

The specification of hemogenic endothelial cells from embryonic vascular endothelium occurs during brief developmental periods within distinct tissues, and is necessary for the emergence of definitive HSPC from the murine extra embryonic yolk sac, placenta, umbilical vessels, and the embryonic aorta-gonad-mesonephros (AGM) region. The transient nature and small size of this cell population renders its reproducible isolation for careful quantification and experimental applications technically difficult. We have established a fluorescence-activated cell sorting (FACS)-based protocol for simultaneous isolation of hemogenic endothelial cells and HSPC during their peak generation times in the yolk sac and AGM. We demonstrate methods for dissection of yolk sac and AGM tissues from mouse embryos, and we present optimized tissue digestion and antibody conjugation conditions for maximal cell survival prior to identification and retrieval via FACS. Representative FACS analysis plots are shown that identify the hemogenic endothelial cell and HSPC phenotypes, and describe a methylcellulose-based assay for evaluating their blood forming potential on a clonal level.

Hematopoietic stem and progenitor cells (HSPC) derive from specialized (hemogenic) endothelial cells during development, yet little is known about the process by which some endothelial cells specify to become blood forming. We demonstrate a flow-cytometry based method allowing simultaneous isolation of hemogenic endothelial cells and HSPC from murine embryonic tissues.

小鼠胚胎Hemogenic内皮细胞的分离

The specification of hemogenic endothelial cells from embryonic vascular endothelium occurs during brief developmental periods within distinct tissues, ...

Protocol for the Direct Conversion of Murine Embryonic Fibroblasts into Trophoblast Stem Cells

Trophoblast stem cells (TSCs) arise as a consequence of the first cell fate decision in mammalian development. They can be cultured in vitro, retaining the ability to self-renew and to differentiate into all subtypes of the trophoblast lineage, equivalent to the in vivo stem cell population giving rise to the fetal portion of the placenta. Therefore, TSCs offer a unique model to study placental development and embryonic versus extra-embryonic cell fate decision in vitro. From the blastocyst stage onwards, a distinct epigenetic barrier consisting of DNA methylation and histone modifications tightly separates both lineages. Here, we describe a protocol to fully overcome this lineage barrier by transient over-expression of trophoblast key regulators Tfap2c, Gata3, Eomes and Ets2 in murine embryonic fibroblasts. The induced trophoblast stem cells are able to self-renew and are almost identical to blastocyst derived trophoblast stem cells in terms of morphology, marker gene expression and methylation pattern. Functional in vitro and in vivo assays confirm that these cells are able to differentiate along the trophoblast lineage generating polyploid trophoblast giant cells and chimerizing the placenta when injected into blastocysts. The induction of trophoblast stem cells from somatic tissue opens new avenues to study genetic and epigenetic characteristics of this extra-embryonic lineage and offers the possibility to generate trophoblast stem cell lines without destroying the respective embryo.

Here we present a protocol for the direct conversion of murine embryonic fibroblasts into fully functional and stable trophoblast stem cells by ten day over-expression of Tfap2c, Gata3, Eomes and Ets2.

协议小鼠胚胎成纤维细胞直接转化为滋养层干细胞

Trophoblast stem cells (TSCs) arise as a consequence of the first cell fate decision in mammalian development. They can be cultured in vitro, retaining ...

Collection of Serum- and Feeder-free Mouse Embryonic Stem Cell-conditioned Medium for a Cell-free Approach

The capacity of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to generate various cell types has opened new avenues in the field of regenerative medicine. However, despite their benefits, the tumorigenic potential of ESCs and iPSCs has long been a barrier for clinical applications. Interestingly, it has been shown that ESCs produce several soluble factors that can promote tissue regeneration and delay cellular aging, suggesting that ESCs and iPSCs can also be utilized as a cell-free intervention method. Therefore, the method for harvesting mouse embryonic stem cell (mESC)-conditioned medium (mESC-CM) with minimal contamination of serum components (fetal bovine serum, FBS) and feeder cells (mouse embryonic fibroblasts, MEFs) has been highly demanded. Here, the present study demonstrates an optimized method for the collection of mESC-CM under serum- and feeder-free conditions and for the characterization of mESC-CM using senescence-associated multiple readouts. This protocol will provide a method to collect pure mESC-specific secretory factors without serum and feeder contamination.

This protocol provides a method for the collection of mouse embryonic stem cell (mESC)-conditioned medium (mESC-CM) derived from serum (fetal bovine serum, FBS)- and feeder (mouse embryonic fibroblasts, MEFs)-free conditions for a cell-free approach. It may be applicable for the treatment of aging and aging-associated diseases.

和无血清收集无饲养小鼠胚胎干细胞条件培养基的无细胞方法

The capacity of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to generate various cell types has opened new avenues in the field ...

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts

Direct reprogramming of one cell type into another has recently emerged as a powerful paradigm for regenerative medicine, disease modeling, and lineage specification. In particular, the conversion of fibroblasts into induced cardiomyocyte-like myocytes (iCLMs) by Gata4, Hand2, Mef2c, and Tbx5 (GHMT) represents an important avenue for generating de novo cardiac myocytes in vitro and in vivo. Recent evidence suggests that GHMT generates a greater diversity of cardiac subtypes than previously appreciated, thus underscoring the need for a systematic approach to conducting additional studies. Before direct reprogramming can be used as a therapeutic strategy, however, the mechanistic underpinnings of lineage conversion must be understood in detail to generate specific cardiac subtypes. Here we present a detailed protocol for generating iCLMs by GHMT-mediated reprogramming of mouse embryonic fibroblasts (MEFs). 
We outline methods for MEF isolation, retroviral production, and MEF infection to accomplish efficient reprogramming. To determine the subtype identity of reprogrammed cells, we detail a step-by-step approach for performing immunocytochemistry on iCLMs using a defined set of compatible antibodies. Methods for confocal microscopy, identification, and quantification of iCLMs and individual atrial (iAM), ventricular (iVM), and pacemaker (iPM) subtypes are also presented. Finally, we discuss representative results of prototypical direct reprogramming experiments and highlight important technical aspects of our protocol to ensure efficient lineage conversion. Taken together, our optimized protocol should provide a stepwise approach for investigators to conduct meaningful cardiac reprogramming experiments that require identification of individual CM subtypes.

This manuscript describes a step-by-step protocol for the generation and quantification of diverse reprogrammed cardiac subtypes using a retrovirus-mediated delivery of Gata4, Hand2, Mef2c, and Tbx5.

评估心肌亚型以下鼠标胚胎成纤维细胞的转录因子介导的重编程

Direct reprogramming of one cell type into another has recently emerged as a powerful paradigm for regenerative medicine, disease modeling, and lineage ...

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Trans-differentiation of one somatic cell type into another has enormous potential to model and treat human diseases. Previous studies have shown that mouse embryonic, dermal, and cardiac fibroblasts can be reprogrammed into functional induced-cardiomyocyte-like cells (iCMs) through overexpression of cardiogenic transcription factors including GATA4, Hand2, Mef2c, and Tbx5 both in vitro and in vivo. However, these previous studies have shown relatively low efficiency. In order to restore heart function following injury, mechanisms governing cardiac reprogramming must be elucidated to increase efficiency and maturation of iCMs.
We previously demonstrated that inhibition of pro-fibrotic signaling dramatically increases reprogramming efficiency. Here, we detail methods to achieve a reprogramming efficiency of up to 60%. Furthermore, we describe several methods including flow cytometry, immunofluorescent imaging, and calcium imaging to quantify reprogramming efficiency and maturation of reprogrammed fibroblasts. Using the protocol detailed here, mechanistic studies can be undertaken to determine positive and negative regulators of cardiac reprogramming. These studies may identify signaling pathways that can be targeted to promote reprogramming efficiency and maturation, which could lead to novel cell therapies to treat human heart disease.

Here we present a robust method to reprogram primary embryonic fibroblasts into functional cardiomyocytes through overexpression of GATA4, Hand2, Mef2c, Tbx5, miR-1, and miR-133 (GHMT2m) alongside inhibition of TGF-&#946; signaling. Our protocol generates beating cardiomyocytes as early as 7 days post-transduction with up to 60% efficiency.

促纤维化信号增强因子介导的小鼠胚胎成纤维细胞再编程诱导心肌细胞的抑制

Trans-differentiation of one somatic cell type into another has enormous potential to model and treat human diseases. Previous studies have shown that ...

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Erythroid cell commitment and differentiation proceed through activation of a lineage-restricted transcriptional network orchestrated by a group of cell fate determining and maturing factors. We previously set out to define the minimal set of factors necessary for instructing red blood cell development using direct lineage reprogramming of fibroblasts into induced erythroid progenitors/precursors (iEPs). We showed that overexpression of Gata1, Tal1, Lmo2, and c-Myc (GTLM) can rapidly convert murine and human fibroblasts directly to iEPs that resemble bona fide erythroid cells in terms of morphology, phenotype, and gene expression. We intend that iEPs will provide an invaluable tool to study erythropoiesis and cell fate regulation. Here we describe the stepwise process of converting murine tail tip fibroblasts into iEPs via transcription factor-driven direct lineage reprogramming (DLR). In this example, we perform the reprogramming in fibroblasts from erythroid lineage-tracing mice that express the yellow fluorescent protein (YFP) under the control of the erythropoietin receptor gene (EpoR) promoter, enabling visualization of erythroid cell fate induction upon reprogramming. Following this protocol, fibroblasts can be reprogrammed into iEPs within five to eight days. 
While improvements can still be made to the process, we show that GTLM-mediated reprogramming is a rapid and direct process, yielding cells with properties of bona fide erythroid progenitor and precursor cells.

Here we present our protocol for producing induced erythroid progenitors (iEPs) from mouse adult fibroblasts using transcription factor-driven direct lineage reprogramming (DLR).

成人小鼠成纤维细胞对红细胞生成子细胞的直接线重编程

Erythroid cell commitment and differentiation proceed through activation of a lineage-restricted transcriptional network orchestrated by a group of cell ...

RNA-based Reprogramming of Human Primary Fibroblasts into Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) have proven to be a valuable tool to study human development and disease. Further advancing iPSCs as a regenerative therapeutic requires a safe, robust, and expedient reprogramming protocol. Here, we present a clinically relevant, step-by-step protocol for the extremely high-efficiency reprogramming of human dermal fibroblasts into iPSCs using a non-integrating approach. The core of the protocol consists of expressing pluripotency factors (SOX2, KLF4, cMYC, LIN28A, NANOG, OCT4-MyoD fusion) from in vitro transcribed messenger RNAs synthesized with modified nucleotides (modified mRNAs). The reprogramming modified mRNAs are transfected into primary fibroblasts every 48 h together with mature embryonic stem cell-specific microRNA-367/302 mimics for two weeks. The resulting iPSC colonies can then be isolated and directly expanded in feeder-free conditions. To maximize efficiency and consistency of our reprogramming protocol across fibroblast samples, we have optimized various parameters including the RNA transfection regimen, timing of transfections, culture conditions, and seeding densities. Importantly, our method generates high-quality iPSCs from most fibroblast sources, including difficult-to-reprogram diseased, aged, and/or senescent samples.

Here we describe a clinically relevant, high-efficiency, feeder-free method to reprogram human primary fibroblasts into induced pluripotent stem cells using modified mRNAs encoding reprogramming factors and mature microRNA-367/302 mimics. Also included are methods to assess reprogramming efficiency, expand clonal iPSC colonies, and confirm expression of the pluripotency marker TRA-1-60.

基于 rna 的人原代成纤维细胞重组成诱导多能干细胞

Induced pluripotent stem cells (iPSCs) have proven to be a valuable tool to study human development and disease. Further advancing iPSCs as a regenerative ...

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

The cellular and molecular mechanisms underlying specification of human hematopoietic stem cells (HSCs) remain elusive. Strategies to recapitulate human HSC emergence in vitro are required to overcome limitations in studying this complex developmental process. Here, we describe a protocol to generate hematopoietic stem and progenitor-like cells from human dermal fibroblasts employing a direct cell reprogramming approach. These cells transit through a hemogenic intermediate cell-type, resembling the endothelial-to-hematopoietic transition (EHT) characteristic of HSC specification. Fibroblasts were reprogrammed to hemogenic cells via transduction with GATA2, GFI1B and FOS transcription factors. This combination of three factors induced morphological changes, expression of hemogenic and hematopoietic markers and dynamic EHT transcriptional programs. Reprogrammed cells generate hematopoietic progeny and repopulate immunodeficient mice for three months. This protocol can be adapted towards the mechanistic dissection of the human EHT process as exemplified here by defining GATA2 targets during the early phases of reprogramming. Thus, human hemogenic reprogramming provides a simple and tractable approach to identify novel markers and regulators of human HSC emergence. In the future, faithful induction of hemogenic fate in fibroblasts may lead to the generation of patient-specific HSCs for transplantation.

This protocol demonstrates the induction of a hemogenic program in human dermal fibroblasts by enforced expression of the transcription factors GATA2, GFI1B and FOS to generate hematopoietic stem and progenitor cells.

通过转录因子的强制表达，人类纤维细胞的造血再编程

The cellular and molecular mechanisms underlying specification of human hematopoietic stem cells (HSCs) remain elusive. Strategies to recapitulate human ...